Bristol Myers Faces Another Trial Disappointment As Heart Drug Milvexian Fails To Show Efficacy

Why did Nvidia's stock surge despite AI bubble fears? How will Ukraine peace plan affect European security? What caused major banks' client data breach? Why are Tesla's China sales plunging? How are AI companies impacting income inequality? What risks do new IRS crypto reporting rules pose? Why is Meta entering electricity trading business?

Bristol Myers Faces Another Trial Disappointment As Heart Drug Milvexian Fails To Show Efficacy

benzinga.com/news/health-care/25/11/48869901/bristol-myers-faces-another-trial-disappointment-as-heart-drug-milvexian-fails-to-show-efficacy

Bristol Myers Squibb & Co. (NYSE:BMY), in collaboration with Johnson & Johnson (NYSE:JNJ), announced Friday that they decided to stop the Phase 3 Librexia ACS trial evaluating the efficacy and safety of milvexian when added to the standard of care (conventional antiplatelet therapy) for…

This story appeared on benzinga.com, 2025-11-14 16:17:52.